Legacy Wealth Asset Management LLC Sells 5,151 Shares of Fresenius Medical Care AG (NYSE:FMS)

Legacy Wealth Asset Management LLC cut its position in shares of Fresenius Medical Care AG (NYSE:FMS) by 13.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 32,897 shares of the company’s stock after selling 5,151 shares during the period. Legacy Wealth Asset Management LLC’s holdings in Fresenius Medical Care were worth $701,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Riverwater Partners LLC boosted its stake in Fresenius Medical Care by 29.5% in the third quarter. Riverwater Partners LLC now owns 16,381 shares of the company’s stock valued at $346,000 after acquiring an additional 3,736 shares in the last quarter. Castleview Partners LLC lifted its holdings in Fresenius Medical Care by 35.9% in the 3rd quarter. Castleview Partners LLC now owns 17,286 shares of the company’s stock valued at $368,000 after purchasing an additional 4,571 shares in the last quarter. Blue Trust Inc. boosted its holdings in shares of Fresenius Medical Care by 1,060.9% during the 3rd quarter. Blue Trust Inc. now owns 12,863 shares of the company’s stock worth $274,000 after purchasing an additional 11,755 shares during the last quarter. ORG Wealth Partners LLC purchased a new stake in shares of Fresenius Medical Care in the third quarter valued at about $112,000. Finally, GAMMA Investing LLC raised its holdings in Fresenius Medical Care by 50.4% in the 3rd quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock valued at $106,000 after buying an additional 1,675 shares during the period. Hedge funds and other institutional investors own 8.25% of the company’s stock.

Fresenius Medical Care Stock Down 2.1 %

Fresenius Medical Care stock opened at $20.92 on Friday. Fresenius Medical Care AG has a twelve month low of $16.37 and a twelve month high of $22.76. The company has a current ratio of 1.46, a quick ratio of 1.09 and a debt-to-equity ratio of 0.45. The stock has a 50 day moving average of $20.20 and a two-hundred day moving average of $20.13. The stock has a market capitalization of $12.28 billion, a price-to-earnings ratio of 23.51, a PEG ratio of 1.06 and a beta of 0.91.

Fresenius Medical Care (NYSE:FMS) last announced its quarterly earnings data on Tuesday, July 30th. The company reported $0.38 EPS for the quarter, meeting analysts’ consensus estimates of $0.38. The firm had revenue of $5.13 billion during the quarter, compared to the consensus estimate of $5.28 billion. Fresenius Medical Care had a net margin of 2.72% and a return on equity of 5.48%. As a group, research analysts expect that Fresenius Medical Care AG will post 1.52 earnings per share for the current year.

Analysts Set New Price Targets

FMS has been the topic of a number of analyst reports. Truist Financial lifted their price objective on Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a research note on Monday, October 7th. StockNews.com initiated coverage on shares of Fresenius Medical Care in a report on Tuesday, October 8th. They issued a “strong-buy” rating on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $23.00.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.